Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.